Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat + Rituximab in R/R DLBCL
NCT01282476Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2011
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Massachusetts General Hospital. Started Jun 2011; status: terminated.
02
Drugs
panobinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01282476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01282476.